From GlobeNewswire: 2025-02-13 13:00:00

Alpha-synuclein inhibitors in clinical trials for neurodegenerative diseases like Parkinson’s disease show promise with 22+ therapies under development. Key companies include Annovis Bio, UCB Biopharma, and more. Recent data from ROME Therapeutics and Vaxxinity demonstrate advancements in novel treatments. Wavebreak’s small molecule, WTX-A, shows potential to reduce toxic protein aggregation in Parkinson’s disease. Dive deeper into alpha-synuclein inhibitors with DelveInsight’s comprehensive report.



Read more at GlobeNewswire: Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel